171 related articles for article (PubMed ID: 36052259)
1. Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring
Fu M; Feng CM; Xia DQ; Ji ZM; Xia HL; Hu NN; Leng ZJ; Xie W; Fang Y; Cao LJ; Zhang JQ
Front Oncol; 2022; 12():954886. PubMed ID: 36052259
[No Abstract] [Full Text] [Related]
2. Use of savolitinib as neoadjuvant therapy for non-small cell lung cancer patient with MET exon 14 skipping alterations: A case report.
Zhang Y; Zhang H; Wang H; Zeng J; Zhang B; Zhou N; Zu L; Song Z; Wang C; Xu S
Front Oncol; 2022; 12():968030. PubMed ID: 36176406
[TBL] [Abstract][Full Text] [Related]
3. Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review.
Tian J; Lin Z; Chen Y; Fu Y; Ding Z
Front Oncol; 2022; 12():1006634. PubMed ID: 36387081
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal-epithelial transition exon 14 skipping mutation: a case report and literature review.
Chen L; Chen JF; He JT; Rong H; Zhuang X; Peng J
Anticancer Drugs; 2024 Jun; 35(5):445-449. PubMed ID: 38385995
[TBL] [Abstract][Full Text] [Related]
5. Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring
Han S; Fang J; Lu S; Wang L; Li J; Cheng M; Ren Y; Su W
Onco Targets Ther; 2019; 12():7323-7328. PubMed ID: 31564914
[TBL] [Abstract][Full Text] [Related]
6. The safety and feasibility of preoperative induction therapy of Savolitinib in non-small cell lung cancer patients with MET exon 14 skipping mutation.
Deng HY; Qiu XM; Zhu DX; Tang XJ; Zhou Q
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4623-4628. PubMed ID: 36171456
[TBL] [Abstract][Full Text] [Related]
7. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Lu S; Fang J; Li X; Cao L; Zhou J; Guo Q; Liang Z; Cheng Y; Jiang L; Yang N; Han Z; Shi J; Chen Y; Xu H; Zhang H; Chen G; Ma R; Sun S; Fan Y; Li J; Luo X; Wang L; Ren Y; Su W
Lancet Respir Med; 2021 Oct; 9(10):1154-1164. PubMed ID: 34166627
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring
Lu S; Fang J; Li X; Cao L; Zhou J; Guo Q; Liang Z; Cheng Y; Jiang L; Yang N; Han Z; Shi J; Chen Y; Xu H; Zhang H; Chen G; Ma R; Sun S; Fan Y; Fan S; Yu J; Lu P; Luo X; Su W
JTO Clin Res Rep; 2022 Oct; 3(10):100407. PubMed ID: 36217329
[TBL] [Abstract][Full Text] [Related]
9. Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration-A Narrative Review.
Zhu X; Lu Y; Lu S
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551608
[TBL] [Abstract][Full Text] [Related]
10. A durable response to savolitinib in a patient with lung adenocarcinoma harboring two novel MET exon 14 skipping sites.
Gu L; Zhao Y; Wen F; Zhang D; Cai J; Chen Z
Anticancer Drugs; 2023 Sep; 34(8):949-953. PubMed ID: 36846984
[TBL] [Abstract][Full Text] [Related]
11. Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib.
Li J; Feng Y; Tan Y; Duan Q; Zhang Q
Front Oncol; 2022; 12():863560. PubMed ID: 35444936
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report.
Wang H; Wu Z; Du Y; Wu T; Tian W; Dong W; Cai J; Zheng J; Zhang Y; Li S; Xu W; Qin J; Xiao Z
Front Oncol; 2023; 13():1145021. PubMed ID: 36969031
[TBL] [Abstract][Full Text] [Related]
13. Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation.
Ren X; Li K; Zhang Y; Zou C; Su M
Front Oncol; 2024; 14():1297156. PubMed ID: 38380365
[TBL] [Abstract][Full Text] [Related]
14. A case of lung adenocarcinoma with MET∆ex14 mutation regressed after preoperative treatment with savolitinib, and successfully underwent radical resection.
Yang F; Chen QF
Anticancer Drugs; 2023 Feb; 34(2):302-305. PubMed ID: 36730552
[TBL] [Abstract][Full Text] [Related]
15. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Yang JJ; Fang J; Shu YQ; Chang JH; Chen GY; He JX; Li W; Liu XQ; Yang N; Zhou C; Huang JA; Frigault MM; Hartmaier R; Ahmed GF; Egile C; Morgan S; Verheijen RB; Mellemgaard A; Yang L; Wu YL
Invest New Drugs; 2021 Apr; 39(2):477-487. PubMed ID: 33052556
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
Zhai H; Zhong W; Yang X; Wu YL
Transl Lung Cancer Res; 2015 Feb; 4(1):82-93. PubMed ID: 25806348
[TBL] [Abstract][Full Text] [Related]
17. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
[TBL] [Abstract][Full Text] [Related]
18. Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:
Safety, Efficacy, and Biomarkers.
Wang Y; Liu T; Chen G; Gong J; Bai Y; Zhang T; Xu N; Liu L; Xu J; He J; Liu Y; Zhang L; Jiang D; Wang M; Chang J; Li W; Bai C; Zhou J; Wang J; Ren Y; Zhang L; Su W; Liu B; Shen L
Oncologist; 2022 Apr; 27(5):342-e383. PubMed ID: 35445725
[TBL] [Abstract][Full Text] [Related]
19. Complete pathological response and negative postoperative ctDNA were not predictive of discontinuation of adjuvant crizotinib therapy in a patient with locally advanced MET ex14 skipping mutation-positive non-small cell lung cancer: a case report.
Wang J; Yao W; Wang W; Fan M; Huang K; Liu Z; Zhu D
Front Oncol; 2023; 13():1164543. PubMed ID: 37554169
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring
Yu Y; Ren Y; Fang J; Cao L; Liang Z; Guo Q; Han S; Ji Z; Wang Y; Sun Y; Chen Y; Li X; Xu H; Zhou J; Jiang L; Cheng Y; Han Z; Shi J; Chen G; Ma R; Fan Y; Sun S; Jiao L; Jia X; Wang L; Lu P; Xu Q; Luo X; Su W; Lu S
Ther Adv Med Oncol; 2022; 14():17588359221133546. PubMed ID: 36339926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]